Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

June 18, 2009

Primary Completion Date

February 18, 2011

Study Completion Date

February 18, 2011

Conditions
Rheumatoid Arthritis
Interventions
OTHER

Placebo

Part 1: Placebo SC administration every 2 weeks X 10 weeks.

DRUG

ILV-094

Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.

DRUG

ILV-094

Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.

OTHER

Placebo

Part 2: Placebo SC administration every 2 weeks X 10 weeks

DRUG

ILV-094

Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks

Trial Locations (52)

1023

Budai Irgalmasrendi Hospital, Budapest

1036

Obudai Egeszsegugyi Centrum Kft, Budapest

1200

Cliniques Universitaires St Luc Avenue Hippocrate 10 UCL, Brussels

2170

AZ Jan Palfijn, Antwerp

3500

Reuma Instituut, Hasselt

4000

Chu Liege Sart Tilman B 35, Liège

4400

Josa Andras Oktatokorhaz Egeszsegugyi Szolgaltato Nonprofit Kft., Nyíregyháza

9000

Universitair Ziekenhuis Gent, Ghent

9700

Markusovszky Hospital, Szombathely

10000

University Hospital Center Zagreb, Zagreb

16635

Altoona Center for Clinical Research, Duncansville

19610

Clinical Research Center of Reading, LLC, Wyomissing

19611

Clinical Research Center of Reading, West Reading

34233

Clinical Research Advantage, Inc., Sarasota

The Arthritis Specialty Centre, Sarasota

34684

Arthritis Center, Palm Harbor

44690

Centro de Estudio de Investigacion Basica y Clinica S.C, Jalisco

45219

Deaconess Hospital, Cincinnati

46227

Diagnostic Rheumatology and Research PC, Indianapolis

51000

University Hospital Centre Rijeka, Rijeka

63117

Clayton Medical Research, St Louis

75231

Arthritis Care and Diagnostic Center, Dallas

78232

Arthritis & Osteoporosis Center of South Texas, San Antonio

80336

Klinikum Innenstadt der Ludwig-Maximillians-Universität, München

85304

Arizona Arthritis & Rheumatology Research, PLLC, Glendale

92260

Desert Medical Advances, Palm Desert

115522

Institute of Rheumatology of Russian academy of Medical Scie, Moscow

119049

City Clinical Hospital # 1 n.a. Pirogov, Moscow

150062

State Healthcare Institution Yaroslavl Regional Clinical Hospital, Yaroslavl

191015

State Educational Institution of Additional Professional Education, Saint Petersburg

194291

State Health care institution of Leningrad Regional Clinical Hospital, Saint Petersburg

214019

State education institution of higher vocational education Smolensk State Medical Academy Roszdrav, Smolensk

400275

Centrul Medical Terra Med, Cluj-Napoca

540136

Spitalul Clinic Judetean de Urgenta Tg Mures, Târgu Mureş

620102

Municipal Institution City Clinical Hospital #40, Yekaterinburg

Unknown

Centro de Reumatologia y Ortopedia, Barranquilla

Fundacion Instituto de Reumatologia Fernando Chalem, Bogota

Medicity S.A.S, Bucaramanga

Servimed EU, Bucaramanga

284-0003

National Hospital Organization Shimoshizu National Hospital, Yotsukaidou

371-8511

Gunma University Hospital, Maebashi

228-8522

National Hospital Organization Sagamihara National Hospital, Sagamihara

712-8044

Medical Corporation Wakoukai Kurashiki Kousai Hospital, Kurashiki

162-0054

Institute of Rheumatology, Tokyo Women's Medical University Hospital, Shinjyuku-ku

370-0053

Inoue Hospital, Gunma

650-0001

Matsubara Clinic, Hyōgo

673-1462

Matsubara Mayflower Hospital, Hyōgo

1105AZ

AMC, Amsterdam

010584

SC Duo Medical SRL, Bucharest

011172

Spitalul Clinic Sf. Maria, Bucharest

020125

Spitalul Clinic Colentina, Bucharest

020983

Centrul de Boli Reumatismale Dr. I. Stoia, Bucharest

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00883896 - Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter